Influenza A virus is a recurrent global health issue, and poses a continual challenge for vaccine design and manufacture. We have previously published our approach to circumvent the issues associated with current inactivated Influenza vaccines, whereby gamma-irradiation is used to inactivate whole Influenza A virus. Our whole inactivated vaccine, termed γ-Flu, provides robust protection against both homotypic and heterosubtypic influenza challenge strains [1, 2]. This cross-protection is primarily mediated by cytotoxic CD8+ T-cell responses [3]. In addition, we have previously reported our novel gamma-irradiated pneumococcal vaccine (γ-PN), which provides serotype independent protection against Streptococcus pneumoniae [4, 5]. In the current study, we illustrate that co-administration of a whole inactivated pneumococcal vaccine (γ-PN) with γ-Flu enhances influenza-specific immunity. Specifically, intranasal co-administration of both γ-PN and γ-Flu resulted in enhanced protection against a severe heterosubtypic influenza challenge, in comparison to vaccination with γ-Flu alone. Our preliminary data suggest that the adjuvant activity of γ-PN is associated with enhanced toll-like receptor 2 (TLR2) signalling and IFN-α. As a large portion of Influenza-related fatalities are due to secondary bacterial infection, this co-vaccination approach could be invaluable in the face of future emerging Influenza pandemics.